Leerink Partnrs Has Negative Outlook of TRVI FY2024 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2024 EPS estimates for shares of Trevi Therapeutics in a report issued on Tuesday, October 15th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings per share of ($0.48) for the year, down from their previous estimate of ($0.46). Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.47) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics' Q4 2024 earnings at ($0.12) EPS, Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.45) EPS and FY2026 earnings at ($0.49) EPS.

Several other research analysts also recently weighed in on TRVI. HC Wainwright assumed coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They issued a "buy" rating and a $6.00 target price for the company. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a "strong-buy" rating in a research note on Monday, August 19th. Raymond James started coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They issued an "outperform" rating and a $9.00 target price for the company. Leerink Partners initiated coverage on Trevi Therapeutics in a research note on Monday, September 9th. They set an "outperform" rating and a $7.00 price target on the stock. Finally, B. Riley reaffirmed a "buy" rating and issued a $6.00 price objective on shares of Trevi Therapeutics in a research report on Monday, October 7th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $7.43.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI remained flat at $3.12 during trading on Friday. The stock had a trading volume of 290,212 shares, compared to its average volume of 260,335. Trevi Therapeutics has a 12 month low of $0.97 and a 12 month high of $4.00. The business's fifty day simple moving average is $3.08 and its 200-day simple moving average is $2.89. The stock has a market capitalization of $219.76 million, a PE ratio of -9.18 and a beta of 0.97.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same period in the previous year, the business posted ($0.07) earnings per share.

Institutional Investors Weigh In On Trevi Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Logos Global Management LP lifted its position in Trevi Therapeutics by 27.3% during the 2nd quarter. Logos Global Management LP now owns 2,800,000 shares of the company's stock worth $8,344,000 after acquiring an additional 600,000 shares in the last quarter. Opaleye Management Inc. raised its stake in shares of Trevi Therapeutics by 4.3% during the first quarter. Opaleye Management Inc. now owns 2,645,000 shares of the company's stock valued at $9,125,000 after purchasing an additional 110,000 shares during the period. Vanguard Group Inc. lifted its position in shares of Trevi Therapeutics by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company's stock worth $7,948,000 after purchasing an additional 60,249 shares in the last quarter. Ally Bridge Group NY LLC purchased a new position in shares of Trevi Therapeutics in the second quarter valued at $4,395,000. Finally, Rosalind Advisors Inc. grew its holdings in Trevi Therapeutics by 50.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company's stock valued at $4,147,000 after purchasing an additional 465,561 shares in the last quarter. Hedge funds and other institutional investors own 95.76% of the company's stock.

Insider Activity at Trevi Therapeutics

In other news, insider Thomas Sciascia sold 18,660 shares of the firm's stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $2.76, for a total value of $51,501.60. Following the transaction, the insider now directly owns 220,315 shares in the company, valued at $608,069.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Trevi Therapeutics news, insider Thomas Sciascia sold 18,660 shares of the business's stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the completion of the sale, the insider now directly owns 220,315 shares in the company, valued at $608,069.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jennifer L. Good sold 10,981 shares of the firm's stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares in the company, valued at approximately $644,205.26. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,355 shares of company stock worth $116,663. 24.37% of the stock is owned by insiders.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.